NanoString nCounter^® Technology

NanoString technology provides a unique way to quickly analyze several hundred distinct gene or protein targets simultaneously using barcoded counting

For preclinical and clinical studies that need highly multiplexed, quantitative gene expression data, NanoString assays can provide rich and useful biomarker data. In addition, NanoString gene expression technology is compatible with low abundance samples like cell-free DNA from liquid biopsies, and low-quality samples such as legacy and FFPE specimens. Precision’s scientific experts can recommend a validated panel or other approach to suit your study and can perform NanoString assays as either an individual service, or as part of a comprehensive therapeutic development package, including biomarker assays and clinical trials.

Advantages of nanoString gene expression assays

Multiplex up to 800 distinct genes
Directly detect RNA for accurate quantitation
Work with old or poor-quality samples, such as FFPE tissue
Work with low-abundance samples such as cfDNA from liquid biopsies
Can utilize predesigned panels of 770 genes (these panels can be customized with an additional 30 genes)
- PanCancer Pathways Panel
- PanCancer Immune Profiling Panel
- PanCancer Progression Panel
- PanCancer IO360™ Gene Expression Panel

Tumor analysis and immune profiling using nanoString technology

By analyzing up to 800 genes (770 standard and up to 30 customized target genes of interest), we can monitor checkpoint inhibitor status and profile the body’s immune response, determining hot/cold tumor status.

Precision specializes in using these and other custom panels to support oncology therapeutic development, as well as to monitor immune status to support development of autoimmune indication therapies.

Autoimmune: Phase 2b clinical study in atopic dermatitis

Antibody therapy targeting effector and memory immune responses. Precision recommended the PanCancer Immune Profiling Panel in conjunction with a custom panel of 14 genes. Result: Determined 4 biomarker key endpoints correlating with patient response.
Oncology: Phase 1/2 clinical trial to determine method of action

Therapy to target patients with metastatic solid tumor. Precision recommended the PanCancer Immune Profiling Panel to analyze 770 genes from 24 different immune cell types, common checkpoint inhibitors, and genes covering both adaptive and innate immune response
Oncology: Phase 1/2 trial in solid tumors

Precision recommended an nCounter Copy Number Variation CodeSet to determine gene copy number in 8 targeted genes in biopsy samples

Global reach, multi-site support

Our ApoStream^® services support preclinical and clinical research, including multi-site studies, conducted anywhere in the world.

Working with Precision

Precision’s specialty lab scientists take a collaborative and consultative approach to projects and can provide recommendations on biomarker assay strategies and implementation. Services can be provided individually or as part of a comprehensive therapeutic development package including biomarker assays and clinical trials.

Explore

ddPCR

Advanced ddPCR applications from preclinical to clinical assays including gene therapy viral shedding and CAR-T biodistribution

Explore

ddPCR

Advanced ddPCR applications from preclinical to clinical assays including gene therapy viral shedding and CAR-T biodistribution

Explore
Explore

NGS

Services including RNA-seq, whole exome sequencing, and targeted DNA/RNA sequencing utilizing both Illumina and Thermo-Fisher NGS platforms

Explore

NGS

Services including RNA-seq, whole exome sequencing, and targeted DNA/RNA sequencing utilizing both Illumina and Thermo-Fisher NGS platforms

Explore
Explore

FISH/ISH

Development of multiplex FISH/ISH assays to detect abnormalities in a range of tissues, including hematological and solid organ tumors

Explore

FISH/ISH

Development of multiplex FISH/ISH assays to detect abnormalities in a range of tissues, including hematological and solid organ tumors

Explore